This company has been marked as potentially delisted and may not be actively trading. Affimed (AFMD) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesOwnershipShort InterestSustainabilityTrendsBuy This Stock AFMD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period OTC:AFMD.Q (Affimed)May 24, 2025 | fool.caAffimed Stock Price, Quotes and ForecastsMay 17, 2025 | benzinga.comCantor Fitzgerald cuts Affimed stock rating on insolvency newsMay 15, 2025 | investing.comAffimed N.V. Files for Insolvency Proceedings Amid Funding ChallengesMay 15, 2025 | nasdaq.comHC Wainwright & Co. Downgrades Affimed N.V. (AFMD)May 15, 2025 | msn.comAffimed N.V.: Affimed Announces Receipt of Nasdaq Delisting NoticeMay 14, 2025 | finanznachrichten.deAffimed (AFMD) Downgraded to Neutral by HC Wainwright & Co. | AFMD Stock NewsMay 14, 2025 | gurufocus.comAffimed (AFMD) Faces Downgrade Amid Insolvency Proceedings | AFMD Stock NewsMay 14, 2025 | gurufocus.comAffimed Announces Receipt of Nasdaq Delisting NoticeMay 14, 2025 | gurufocus.comAffimed Announces Receipt of Nasdaq Delisting Notice | AFMD Stock NewsMay 14, 2025 | gurufocus.comAffimed (AFMD) Faces Delisting from Nasdaq | AFMD Stock NewsMay 14, 2025 | gurufocus.comAffimed Announces Receipt of Nasdaq Delisting NoticeMay 14, 2025 | globenewswire.comAffimed N.V.: Affimed Announces Filing for the Opening of Insolvency ProceedingsMay 14, 2025 | finanznachrichten.deLeerink Partners Downgrades Affimed N.V. (AFMD)May 13, 2025 | msn.comWells Fargo Downgrades Affimed (AFMD) with New Price Target | AFMD Stock NewsMay 13, 2025 | gurufocus.comAffimed Shares Down, Halted in Premarket on Bankruptcy ApplicationMay 13, 2025 | marketwatch.comAffimed (AFMD) Files for Insolvency Amid Financial ChallengesMay 13, 2025 | gurufocus.comAffimed Announces Filing for the Opening of Insolvency ProceedingsMay 13, 2025 | globenewswire.comAffimed Delays Filing of 2024 Yearly ReportMay 1, 2025 | tipranks.comAFM24 shows promise in advanced lung cancer treatmentApril 30, 2025 | investing.comAffimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual MeetingApril 29, 2025 | globenewswire.comAffimed Announces Acceptance of Three Abstracts for Presentation at the American Society for ...April 23, 2025 | gurufocus.comAffimed Announces Acceptance of Three Abstracts for Presentation at the American Society for ...April 23, 2025 | gurufocus.comAffimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual MeetingApril 23, 2025 | globenewswire.comAffimed receives Nasdaq notice of non-complianceApril 21, 2025 | markets.businessinsider.comAffimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait ModeApril 21, 2025 | msn.comAffimed Faces Nasdaq Delisting Risk Due to Share PriceApril 21, 2025 | tipranks.comAffimed (AFMD) Faces Nasdaq Delisting Risk Over Share PriceApril 21, 2025 | gurufocus.comAffimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementApril 21, 2025 | gurufocus.comAffimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock NewsApril 21, 2025 | gurufocus.comAffimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | ...April 21, 2025 | gurufocus.comAffimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price ComplianceApril 21, 2025 | quiverquant.comQAffimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementApril 21, 2025 | globenewswire.comAffimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual MeetingMarch 25, 2025 | globenewswire.comAffimed to Present at the Leerink Partners Global Healthcare Conference 2025March 3, 2025 | globenewswire.com683 Capital Management, LLC Reduces Stake in Affimed NVFebruary 14, 2025 | gurufocus.comAnalyst revises Affimed Therapeutics stock price target amid AFM24 trial progressionDecember 20, 2024 | uk.investing.comAffimed price target lowered to $11 from $15 at Wells FargoDecember 19, 2024 | markets.businessinsider.comAffimed (AFMD) Gets a Buy from Truist FinancialDecember 19, 2024 | markets.businessinsider.comAffimed’s AFM24/atezolizumab combination shows positive results in NSCLC trialDecember 18, 2024 | markets.businessinsider.comAffimed price target lowered to $7 from $10 at H.C. WainwrightDecember 18, 2024 | tipranks.comAffimed’s Promising Clinical Update on NSCLC TreatmentDecember 18, 2024 | markets.businessinsider.comAffimed Shares Fall 32% on Clinical UpdateDecember 18, 2024 | finance.yahoo.comAffimed stock plunges 23% on AFM24 study updateDecember 18, 2024 | msn.comAffimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)December 17, 2024 | markets.businessinsider.comAffimed Reports Positive Data From AFM24-102 Trial In Heavily Pretreated NSCLC PatientsDecember 17, 2024 | markets.businessinsider.comAffimed price target lowered to $15 from $20 at Wells FargoDecember 12, 2024 | tipranks.comAffimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28December 9, 2024 | tipranks.comAffimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)December 9, 2024 | globenewswire.comAffimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerDecember 9, 2024 | globenewswire.com Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AFMD Media Mentions By Week AFMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AFMD News Sentiment▼0.000.99▲Average Medical News Sentiment AFMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AFMD Articles This Week▼02▲AFMD Articles Average Week Get the Latest News and Ratings for AFMD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Affimed and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies LGVN News Today SONN News Today IXHL News Today BCDA News Today LPTX News Today SNSE News Today PCSA News Today INAB News Today TRAW News Today PHXM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AFMD) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access